Emergent BioSolutions | EBS - Cash And Equivalent


Emergent BioSolutions reported $111.7M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
ANI Pharmaceuticals USD 285.58M 22.98M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Exelixis USD 482.49M 106.19M Dec/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
Lonza CHF 719M 188M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Myriad Genetics USD 149.6M 4.2M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pacira USD 158.54M 10.96M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024